MNTA: After further reflection, I strongly suspect that the aforementioned, first 3 items, will likely occur within the next 30 days (and equating to roughly 6 months post-FDA notification):
1. MNTA decides on a final path forward based on FDA discussions and discloses such to investors.
2. MNTA discloses that it has submitted all additional data to the FDA for review.
3. Appellette Court affirms patent decision on Lovenox. (My assumption)
Not included: Analyst's regaining a bullish stance and weighing in, having jumped off the bandwagon after declaring a possible need for human trials and a 6-18 month delay...
Market Data 
Markets 
AI
